Kaiapoi (NZ)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~14 mi. (Christchurch, New Zealand, +226 more cities)
facility
Canterbury Regional Cancer & Blood Service ( Site 0195)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~14 mi. (Christchurch, New Zealand, +199 more cities)
facility
Christchurch Hospital ( Site 0247)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
city
~14 mi. (Christchurch, New Zealand, +59 more cities)
facility
New Zealand Clinical Research (Christchurch)
biomarker
BRAF V600E, +1 more biomarker
condition
Cutaneous Melanoma
drug
binimetinib, +2 more drugs
drug type
immunotherapy, +1 more type